Familial hypercholesterolemia (FH), caused by mutations in the low-density lipoprotein receptor (LDLr) gene, has been increasingly associated with neurodegenerative and mood disorders. Studies with LDLR knockout mice (LDLr −/− ) showed that neuroinflammation is a key event in FH-related brain dysfunction. Because mTOR inhibition has been shown to mitigate brain alterations in this model, we hypothesized that metformin, a drug reported to influence cellular energy metabolism, could attenuate FH-associated brain changes. To test this, adult LDLr −/− mice received daily oral doses of metformin (200 mg/Kg) or vehicle for 30 days. During the final week, behavioral assessments were conducted, including the open-field test, novel object recognition and object reallocation tasks, and the tail suspension test (depressive-like behavior). Body weight, total cholesterol and glucose plasma levels were analyzed. Hippocampal astrocyte and microglial density, as well as the expression of genes related to neuroinflammation and synaptic plasticity, were evaluated. Metformin did not alter total cholesterol levels but significantly improved cognitive performance and reduced depressive-like behavior. The treatment also attenuated hippocampal astrogliosis without affecting microglial reactivity. Molecular analysis revealed reduced hippocampal TGF-β gene expression and increased PSD-95 gene expression and protein content in metformin-treated LDLr −/− mice. Although a slight, non-significant reduction in the phosphorylated-to-total mTOR ratio was detected, no clear evidence of AMPK/mTOR pathway modulation was observed. Overall, metformin improved memory function and astrocyte reactivity in LDLr −/− mice independently of cholesterol reduction and without demonstrable involvement of the AMPK/mTOR pathway, suggesting its potential as a therapeutic strategy for FH-associated brain dysfunction.
Background/Objectives: Dysregulation of purinergic signaling, particularly CD73 overexpression, influences tumor progression, immune evasion, and chemoresistance in hepatocellular carcinoma (HCC). We aimed to characterize the transcriptional landscape of this system, identify prognostic markers, and investigate how the tumor microenvironment modulates pharmacological response to combined sorafenib and doxazosin in 3D spheroid models. Methods: We integrated RNA-seq data from The Cancer Genome Atlas—Liver Hepatocellular Carcinoma (TCGA-LIHC) to identify differentially expressed genes, pathway enrichment, gene co-expression networks, prognostic associations, and machine learning-based biomarker selection. Modulation of key targets was assessed in HepG2 and HepG2/LX-2 spheroids treated with sorafenib and doxazosin using qPCR and flow cytometry. Results: Transcriptomics revealed dysregulation and network fragmentation. Specifically, analysis of the TCGA cohort indicated that high expression of ADA, NT5E, and ADORA1 correlated with poor overall survival. Given the critical role of CD73 in therapy resistance, we evaluated these findings in 3D models. Co-treatment significantly downregulated NT5E and ADORA1 mRNA expression, while ADORA2A was specifically reduced in the co-culture setting. For the ADA, effect-size analysis revealed a large magnitude of inhibition in HepG2 spheroids. Although flow cytometry showed that high CD73 protein expression remained stable across treatments in co-culture, the combination therapy overcame stromal protection, significantly increasing apoptosis (active caspase-3) in both mono- and co-culture spheroids compared with vehicle and monotherapy. Conclusions: We identified a purinergic prognostic signature in HCC and demonstrated that the combination therapy of sorafenib and doxazosin targets the adenosine pathway and specific receptors. We show that the stromal microenvironment sustains CD73 protein expression even under transcriptional inhibition, highlighting the critical role of 3D co-culture models in deciphering therapeutic resistance mechanisms.
Background: Low‐density lipoprotein (LDL) is responsible for the transport of cholesterol to peripheric tissues (Cortes et al. 2014), and it enters the cells via LDL receptors (LDLr) (Luo, Yang, Song 2020). Cholesterol metabolism alterations, i.e., hypercholesterolemia are well‐known cardiovascular risk factors and have also been linked to cognitive and behavioral alterations (De Oliveira et al. 2011, Sparks et al. 1990, WHO 2008). Familial hypercholesterolemia (FH) is a prevalent disease caused by dysfunctions of cholesterol metabolism (Akioyamen et al. 2017), and several reports show its connection to neuroinflammation (Ariza et al. 2016, De Oliveira et al. 2020). Recent studies associate mTOR inhibition with conservation of blood‐brain barrier integrity, cognitive damage attenuation, and systemic and cerebral inflammation reduction in dementia and FH animal models (Jahrling et al. 2018, Van Skike et al. 2018). In this regard, Metformin presents critical therapeutic potential because it inhibits mTOR through AMPK.Objective: Evaluation of Metformin treatment on cognitive disturbances and central and peripheric biochemical parameters in C57BL/6 LDLr deficient (LDLr‐/‐) mice.Method: LDLr‐/‐ and wild‐type (WT) male mice (3‐month‐old, 20‐3 g) received a daily oral administration via gavage of Metformin (200 mg/kg) or Saline for 30 days. All animals were weighed weekly. Mice were submitted to behavioral tasks in the last week of treatment. Following the last day of treatment, animals fasted for 12 hours and were euthanized by cardiac exsanguination. Heparinized plasma was used to determine total cholesterol and triglyceride levels. Another cohort of animals was perfused with paraformaldehyde to collect fixed total brains, which were used in immunofluorescence assays for labeling glial fibrillary acidic protein (GFAP).Result: LDLr‐/‐ mice showed higher total cholesterol levels compared to WT groups. Metformin treatment increased triglyceride levels and decreased total body weight in LDLr‐/‐ mice in comparison to Saline administration. LDLr‐/‐ mice showed hyperlocomotive activity, cognitive damage, and a depressed phenotype, which was in parts attenuated by Metformin treatment. Metformin treatment ameliorated astrogliosis in the hippocampus of LDLr‐/‐ mice.Conclusion: Metformin treatment showed a promising effect on the memory impairment and astrocyte reactivity observed in LDLr‐/‐ mice, which was not via a cholesterol‐lowering outcome.
Background: Hepatic stellate cells (HSCs) are major regulators of the hepatocellular carcinoma (HCC) tumor microenvironment, contributing to extracellular matrix remodeling, tumor progression, and therapeutic resistance. Although three-dimensional (3D) coculture spheroid models better represent tumor-stroma interactions than conventional monocultures, the impact of HSCs on spheroid architecture and function remains incompletely characterized. This study investigated how HSCs influence the structural and functional properties of a 3D HCC model. Methods and results: Spheroids were produced using HepG2 cells, LX-2 cells (HSCs), or a 1:1 coculture system (CCS) and characterized over 96 h. Morphometric analysis demonstrated that CCS spheroids exhibited reduced area and perimeter together with increased circularity and normalized solidity, indicating enhanced structural organization and compaction. Scanning electron microscopy (SEM) confirmed distinct ultrastructural organization among the spheroid models. Flow cytometry revealed fewer membrane-compromised cells in CCS spheroids than in HepG2 spheroids. Although the percentage of active caspase−3-positive cells was unchanged, active caspase−3 fluorescence intensity was lower in both HepG2-like and LX-2-like populations. CCS spheroids showed higher collagen type I alpha-1-associated fluorescence, predominantly in the α-SMA-positive compartment, consistent with a stromal collagen-producing phenotype. Biochemical analyses revealed distinct extracellular lactate profiles. Extracellular LDH activity was lower in CCS spheroids than in HepG2 spheroids, although normalized LDH release did not differ between these groups. Functionally, CCS spheroids displayed reduced sorafenib sensitivity, with an IC30 approximately 3-fold higher than HepG2 monoculture. Conclusions: LX-2 incorporation was associated with greater spheroid organization, increased collagen type I-related expression, altered cell-death and extracellular metabolic profiles, and reduced sorafenib sensitivity, supporting the value of HepG2/LX-2 coculture spheroids for studying selected tumor–stromal interactions.
Background/Objectives: Dysregulation of purinergic signaling influences tumor progression and immune evasion in hepatocellular carcinoma (HCC). We aimed to characterize the transcriptional landscape of this system, identify prognostic markers, and investigate how the tumor microenvironment modulates pharmacological response to combined sorafenib and doxazosin in 3D spheroid models. Methods: We integrated RNA-seq data from the TCGA-LIHC to identify differentially expressed genes, pathway enrichment, gene co-expression networks, prognostic associations, and machine learning-based biomarker selection. Modulation of key targets was assessed in HepG2 and HepG2/LX-2 spheroids treated with sorafenib and doxazosin using qPCR and flow cytometry. Results: Transcriptomics revealed dysregulation and network fragmentation, where high expression of ADA, NT5E, and ADORA1 correlated with poor overall survival. In 3D models, co-treatment significantly downregulated NT5E and ADORA1 mRNA expression, while ADORA2A was specifically reduced in the co-culture setting. For ADA, effect size analysis revealed a large magnitude of inhibition in HepG2 spheroids. Although flow cytometry showed high CD73 protein expression remained stable across treatments in co-culture, the combination therapy successfully overcame stromal protection, significantly increasing apoptosis (active caspase-3) in both mono- and co-culture spheroids compared to vehicle and monotherapy. Conclusions: We identified a purinergic prognostic signature in HCC and demonstrated that the combination therapy of sorafenib and doxazosin targets the adenosine-generating axis and specific receptors. We show that the stromal microenvironment sustains CD73 protein expression even under transcriptional inhibition, highlighting the critical role of 3D co-culture models in deciphering therapeutic resistance mechanisms.